Back

Positioning PCSK9 inhibitors therapy in clinical practice.

2 September 2019 (09:42 - 10:00)
Organised by:
Congress Presentation Part of: PCSK9 inhibitors: from cells to patients PCSK9-Antagonists ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
State of the Art - PCSK9 in inhibitors therapy in clinical therapy
Professor S. Nicholls (Melbourne, AU)
Slides Video
Presentation thumbnail
The effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors on endothelial progenitor cells
Doctor O. Itzhaki Ben Zadok (Petah Tikva, IL)
Abstract
Presentation thumbnail
The effect of monoclonal antibodies against PCSK9 on circulating CD34+ progenitor cells interactions with platelets in patients with familial hypercholesterolemia.
Mrs A. Tsouka (Ioannina, GR)
Abstract Slides Video
Presentation thumbnail
Treatment of Hypercholesterolaemia with PCSK9 Inhibitors in Denmark. Assessment of real-life data; Extent and Efficacy after the first years of clinical use
Doctor S. Mulverstedt (Copenhagen, DK)
Abstract

Access the full session

Session thumbnail
PCSK9 inhibitors: from cells to patients

The Event

Event poster

ESC Congress 2019

2 September 2019 09:42 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy of PCSK9 inhibitors combined with statins versus statin monotherapy for secondary cardiovascular prevention: a systematic review and meta-analysis
thumbnail
Congress Presentation
Longer-term impact of PCSK9 inhibitors on major adverse cardiovascular events and all-cause mortality: a systematic review and meta-analysis of randomised controlled trials
thumbnail
Congress Presentation
PCSK9 inhibition: new insights